TriSalus Life Sciences, Inc. 8-K

What Happened
TriSalus Life Sciences, Inc. filed an 8-K on April 7, 2026 announcing that it entered into an offer letter with Dr. Richard Marshall on April 1, 2026 to serve as Chief Medical Officer. Dr. Marshall’s employment is expected to begin June 29, 2026. The company also issued a press release on April 7, 2026 announcing the appointment.

Key Details

• Start date: June 29, 2026. Offer letter dated April 1, 2026; press release dated April 7, 2026.
• Cash compensation: $525,000 annual base salary and a $250,000 sign-on bonus.
• Bonus and equity: Eligible for an annual bonus up to 50% of base salary (board-determined); company will recommend a grant of 120,000 stock options and 60,000 restricted stock units; eligible for annual equity grants under the Equity Incentive Plan, subject to Board approval.
• Corporate governance note: The company reported no related-party transactions with Dr. Marshall requiring disclosure under Item 404(a).

Why It Matters
For investors, the filing signals a senior clinical hire that could strengthen TriSalus’s medical and clinical leadership as the company advances its programs. The disclosed compensation and prospective equity awards show the near-term cash and potential equity cost — useful for assessing executive expenses and possible dilution if equity grants are approved. The equity grants and bonus are subject to Board approval, so final awards and their timing will depend on future Board actions.